Pharmaceutical Executive

Pharmaceutical Executive Daily: Novo Partners with Anthropic

Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reim

Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership

GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why

Pharmaceutical Executive Daily: Novo Nordisk Enters Rebrand

Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie

Pharmaceutical Executive Daily: Novartis Shareholders Raise Concerns over M&A Strategy

Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan argues health care needs an orchestration layer ra

Pharmaceutical Executive Daily: David Samra Calls For Novartis Board Shake-Up

340B Under Pressure: Inside Pharma's Push for Greater Clarity

In this episode of Pricing & Policy with Model N, Jesse Mendelsohn, senior vice president at Model N, joins host Mike Christel to examine the growing stakes surrounding t

Pharmaceutical Executive Daily: Moonwalk Biosciences' $70 Million Series B

Aptar Pharma and Aceso Therapeutics team up to advance an inhaled cystic fibrosis therapy, Moonwalk Biosciences raises a $70 million Series B for its fat-targeted obesity

Pharmaceutical Executive Daily: FDA Approves Zanvastro

Ionis wins FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, Pharmaceutical Executive’s weekly biotech roundup gathers analyst reac

Pharmaceutical Executive Daily: Ultragenyx's Apazunersen Fails Phase III Trial

Ultragenyx shares plunge after apazunersen fails its Phase III trial in Angelman syndrome, Mark Cziraky of Carelon Research talks through the mechanics of analyzing linke

The Ron Lanton Report: What Are We Doing This All For?

Melanie Whittington, managing director and head of the Leerink Center for Pharmacoeconomics, joins Ron Lanton to argue that biopharmaceutical policy only makes sense when

Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials

Novartis and Bristol Myers Squibb pause autoimmune CAR-T trials over safety concerns, a dealmaking roundup covers Alteogen's licensing deal with Novartis, NewBiologix's g

Pharmaceutical Executive Daily: Nine Companies Strike Deals for MFN Pricing

The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA flu vaccine into Phase III, and Simcere Zaimi

Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences

Eli Lilly agrees to acquire Merida Biosciences for up to $2.875 billion, BioNTech halts a Phase II trial of its cancer immunotherapy Cevumeran, and Parth Khanna argues th

Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals

FDA approves three new therapies spanning autoimmune disease, HIV, and cardiovascular risk, DualityBio and Teva strike major biopharma deals, and Israel Ortiz makes the c

Pharmaceutical Executive Daily: President Trump Planning New Medicaid Drug-Pricing Deals

Osivax and GC Biopharma team up on a next-generation flu vaccine, K2 Therapeutics' Ying Huang talks through why so few drugs make it to market, and the Trump administrati

Pharmaceutical Executive Daily: Haisco Licenses Preclinical Immunology Asset to Sentivera

A new Eli Lilly study links Zepbound to lower healthcare costs in older adults with obesity, Biohaven and Haisco strike major licensing deals with SK Biopharmaceuticals a

Pharmaceutical Executive Daily: FDA Approves Imaavy for wAIHA

FDA approves Imaavy as the first treatment for warm autoimmune hemolytic anemia, McKesson agrees to acquire Precision Medicine Group as Lundbeck partners with Eversana on

Pharmaceutical Executive Daily: Hanmi Licenses HM17321 to Genentech

Hanmi Pharm licenses its obesity drug candidate HM17321 to Genentech, James LaValle weighs in after FDA advisors back most nominated peptides for the compounding bulks li

Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly

Amplitude Therapeutics and Chai Discovery ink AI and RNA collaborations with Eli Lilly and Bristol Myers Squibb, Norstella's Dan Chancellor makes the case for dealmaking

Pharmaceutical Executive Daily: FDA Approves Pasatru

A partnership roundup covers deals from IntraGel Therapeutics/UroGen Pharma and Lupin/Tenpoint Therapeutics, FDA approves Regeneron's Pasatru for fibrodysplasia ossifican